Sequana Medical NV (FRA:2SE) Total Long-Term Assets: €3.99 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2SE Sequana Medical NV FRA:2SE
31 GF Score
Price €0.51
GF Value €0.19
! 12 Warning Signs
View Full Analysis

What is Sequana Medical NV Total Long-Term Assets?

Sequana Medical NV FRA:2SE 31 Total Long-Term Assets is €3.99 Mil as of Jun. 2025. GuruFocus rates FRA:2SE with a GF Score™ of 31/100 and a GF Value™ of €0.19. The stock has 12 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Sequana Medical NV's Total Long-Term Assets for the quarter that ended in Jun. 2025 was €3.99 Mil.

Sequana Medical NV Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Sequana Medical NV's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sequana Medical NV Total Long-Term Assets Chart

Sequana Medical NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.77 1.81 2.94 3.81 3.53

Sequana Medical NV Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.23 3.81 3.64 3.53 3.99
FRA:2SE
31GF Score
Sequana Medical NV FRA:2SE
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sequana Medical NV Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €3.99 Mil mean?
Sequana Medical NV (FRA:2SE) has a Total Long-Term Assets of €3.99 Mil as of Jun. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Sequana Medical NV and its competitors.
Is Sequana Medical NV's Total Long-Term Assets too high?
Sequana Medical NV's current Total Long-Term Assets is €3.99 Mil. Overall, Sequana Medical NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Sequana Medical NV's Total Long-Term Assets compare to ABT and SYK?
Sequana Medical NV's Total Long-Term Assets of €3.99 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Medical Devices & Instruments company?
A good Total Long-Term Assets depends on the Medical Devices & Instruments industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Sequana Medical NV and its competitors. Sequana Medical NV's current Total Long-Term Assets is €3.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sequana Medical NV stock overvalued right now?
Sequana Medical NV (FRA:2SE) has a current Total Long-Term Assets of €3.99 Mil. The stock's GF Value™ is €0.19, compared to a current price of €0.51 — trading 169.5% above its estimated fair value. The current Total Long-Term Assets is €3.99 Mil. Sequana Medical NV's overall GF Score™ is 31/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Sequana Medical NV (FRA:2SE), the current Total Long-Term Assets is €3.99 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sequana Medical NV (FRA:2SE) Overvalued in 2026?

Based on GuruFocus' analysis, Sequana Medical NV stock appears to be overvalued. The current stock price of €0.51 is trading 169.5% above its estimated GF Value™ of €0.19.

Key valuation signals for FRA:2SE:

  • Total Long-Term Assets: €3.99 Mil
  • GF Value™: €0.19 vs. price of €0.51 (169.5% above fair value)
  • GF Score™: 31/100 with 12 warning signs

No single metric tells the full story. See the FRA:2SE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sequana Medical NV Business Description

Other Exchanges 2SE:GermanySEQUA:Belgium
Address Kortrijksesteenweg 1112, bus 102, Sint-Denijs-Westrem, Ghent, BEL, 9051
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.
31GF Score

Get the complete analysis for FRA:2SE

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price
€0.19
GF Value